Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Riveiro-Barciela M, Barreira-Díaz A, Salcedo MT, Callejo-Pérez A, Muñoz-Couselo E, Iranzo P, Ortiz-Velez C, Cedrés S, Díaz-Mejía N, Ruiz-Cobo JC, Morales R, Aguilar-Company J, Zamora E, Oliveira M, Sanz-Martínez MT, Viladomiu L, Martínez-Gallo M, Felip E, Buti M. Riveiro-Barciela M, et al. Among authors: felip e. Aliment Pharmacol Ther. 2024 Apr;59(7):865-876. doi: 10.1111/apt.17898. Epub 2024 Feb 7. Aliment Pharmacol Ther. 2024. PMID: 38327102
Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid Tumors.
Carreras MJ, Renedo-Miró B, Valdivia C, Tomás-Guillén E, Farriols A, Mañós L, Vidal J, Alcalde M, De la Paz I, Jiménez-Lozano I, Palacio-Lacambra ME, Sabaté N, Felip E, Garralda E, Garau M, Gorgas MQ, Monterde J, Tabernero J. Carreras MJ, et al. Among authors: felip e. Cancers (Basel). 2024 Apr 17;16(8):1529. doi: 10.3390/cancers16081529. Cancers (Basel). 2024. PMID: 38672610 Free PMC article.
RET Fusion Testing in Patients With NSCLC: The RETING Study.
Conde E, Hernandez S, Rodriguez Carrillo JL, Martinez R, Alonso M, Curto D, Jimenez B, Caminoa A, Benito A, Garrido P, Clave S, Arriola E, Esteban-Rodriguez I, De Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, Garcia-Gonzalez J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan-Vidal O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Paz-Ares L, Lopez-Rios F. Conde E, et al. Among authors: felip e. JTO Clin Res Rep. 2024 Feb 20;5(4):100653. doi: 10.1016/j.jtocrr.2024.100653. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38525319 Free PMC article.
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Solomon BJ, et al. Among authors: felip e. J Clin Oncol. 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581. Online ahead of print. J Clin Oncol. 2024. PMID: 38819031
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, Molden N, Daggumati P, Connolly W, Johnson M, Abreu DR, Cho BC, Italiano A, Gil-Bazo I, Felip E, Mellman I, Mariathasan S, Shames DS, Meng R, Chiang EY, Johnston RJ, Patil NS. Guan X, et al. Among authors: felip e. Nature. 2024 May 30. doi: 10.1038/s41586-024-07562-2. Online ahead of print. Nature. 2024. PMID: 38816613 No abstract available.
The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project.
Sebri V, Marzorati C, Dorangricchia P, Monzani D, Grasso R, Prelaj A, Provenzano L, Mazzeo L, Dumitrascu AD, Sonnek J, Szewczyk M, Watermann I, Trovò F, Dollis N, Sarris E, Garassino MC, Bestvina CM, Pedrocchi A, Ambrosini E, Kosta S, Felip E, Soleda M, Roca AA, Rodríguez-Morató J, Nuara A, Lourie Y, Fernandez-Pinto M, Aguaron A, Pravettoni G. Sebri V, et al. Among authors: felip e. Cancer Med. 2024 May;13(9):e7159. doi: 10.1002/cam4.7159. Cancer Med. 2024. PMID: 38741546 Free PMC article. Review.
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced/Metastatic NSCLC.
Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Herraez-Baranda LA, Shearer-Kang E, Liu X, Tosti N, Williams P, Castro Sanchez AY, Zanghi J, Felip E. Burotto M, et al. Among authors: felip e. J Thorac Oncol. 2024 May 8:S1556-0864(24)00210-7. doi: 10.1016/j.jtho.2024.05.005. Online ahead of print. J Thorac Oncol. 2024. PMID: 38729426 Free article.
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation.
Peters S, Loi S, André F, Chandarlapaty S, Felip E, Finn SP, Jänne PA, Kerr KM, Munzone E, Passaro A, Pérol M, Smit EF, Swanton C, Viale G, Stahel RA. Peters S, et al. Among authors: felip e. Ann Oncol. 2024 Apr 20:S0923-7534(24)00108-X. doi: 10.1016/j.annonc.2024.04.002. Online ahead of print. Ann Oncol. 2024. PMID: 38648979 Review.
548 results